retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Guide 2023: Weight Loss, Benefits, Results, Dosage Upcoming wave of hormone-based therapies
Description
Retatrutide (also known as LY3437943) is an investigational medicine being studied for obesity and metabolic disease
Adherence and Convenience Drive Long-Term Market Share Obesity is a chronic condition requiring indefinite treatment
GLP-1 medications are often used specifically to promote weight loss, and the metabolic changes accompanying that process can affect bone turnover and lower bone density, says Dr
This trial underscores the expanding scope of incretin therapy beyond simple weight management, a trend also visible in the growing body of research on peptides for athletic performance and recovery
